Leukocytociastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib

被引：20

作者：

Chung, Nancy M.

Gutierrez, Martin

Turner, Maria L.

机构：

来源：

ARCHIVES OF DERMATOLOGY | 2006年 / 142卷 / 11期

关键词：

D O I：

10.1001/archderm.142.11.1510

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

收藏

页码：1510 / 1511

页数：2

相关论文

共 5 条

[1] Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours [J].

Awada, A ;

Hendlisz, A ;

Gil, T ;

Bartholomeus, S ;

Mano, M ;

de Valeriola, D ;

Strumberg, D ;

Brendel, E ;

Haase, CG ;

Schwartz, B ;

Piccart, M .

BRITISH JOURNAL OF CANCER, 2005, 92 (10) :1855-1861

[2] Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors [J].

Moore, M ;

Hirte, HW ;

Siu, L ;

Oza, A ;

Hotte, SJ ;

Petrenciuc, O ;

Cihon, F ;

Lathia, C ;

Schwartz, B .

ANNALS OF ONCOLOGY, 2005, 16 (10) :1688-1694

[3] Cutaneous side-effects of kinase inhibitors and blocking antibodies [J].

Robert, C ;

Soria, JC ;

Spatz, A ;

Le Cesne, A ;

Malka, D ;

Pautier, P ;

Wechsler, J ;

Lhomme, C ;

Escudier, B ;

Boige, V ;

Armand, JP ;

Le Chevalier, T .

LANCET ONCOLOGY, 2005, 6 (07) :491-500

[4] Targeted agents for the treatment of advanced renal cell carcinoma [J].

Staehler, M ;

Rohrmann, K ;

Haseke, N ;

Stief, CG ;

Siebels, M .

CURRENT DRUG TARGETS, 2005, 6 (07) :835-846

[5] Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? [J].

Strumberg, D ;

Awada, A ;

Hirte, H ;

Clark, JW ;

Seeber, S ;

Piccart, P ;

Hofstra, E ;

Voliotis, D ;

Christensen, O ;

Brueckner, A ;

Schwartz, B .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (04) :548-556